Use of sacubitril/valsartan in non-compaction cardiomyopathy: a case report.
The use of sacubitril/valsartan significantly reduces death or hospitalization in patients with ejection fraction < 40%. There is no study evaluating this drug effects in non-compaction cardiomyopathy (NCCM) individuals. The aim of this article is to report a case of a patient with NCCM initially refractory to gold standard treatment and afterwards treated with sacubitril/valsartan and its improvements. This is a case report of a 48-year-old woman, presenting with NCCM heart failure, who had received standard guideline-directed medical therapy for 18 months without any improvement in clinical and echocardiographic parameters. After that period, sacubitril/valsartan was initiated. After 18 months of refractory usage of guideline-directed medical therapy, sacubitril/valsartan was started, and significant change in functional class (III to I) and important ventricular remodelling were achieved with an improvement of 29% in the ejection fraction, reduction of 7 mm in ventricular diastolic diameter, and mild to none mitral valve functional regurgitation. In this case report, sacubitril/valsartan use was associated with improvement of echocardiographic and clinical parameters in a patient with NCCM.
['Bonatto|Marcely Gimenes|MG|', 'Albanez|Rodrigo|R|', 'Salemi|Vera Maria Cury|VMC|', 'Moura|Lídia Zytynski|LZ|']
D000613:Aminobutyrates D057911:Angiotensin Receptor Antagonists D001713:Biphenyl Compounds D009202:Cardiomyopathies D004338:Drug Combinations D005260:Female D006801:Humans D008875:Middle Aged D013318:Stroke Volume D000068756:Valsartan
Sacubitril/valsartan non-compaction cardiomyopathy Heart failure Reverse remodelling